Keyword: Alex Gorsky

J&J's CEO said this week the pharma industry needs to police itself on pricing. Days later, his company raised prices on two dozen drugs.

What's bad for Johnson & Johnson shares is good for the trial lawyer leading the charge in the talc liability litigation—or so the lawyer says.

Investors sent J&J's shares down Friday after Reuters reported on court documents detailing the company's internal debates over asbestos in talc.

J&J CEO Alex Gorsky said Amazon could offer expertise in distribution as well as shake up reimbursement in a potential pharma entry.

Two talcum cases have ended in mistrials in recent weeks as juries failed to determine whether marketer J&J is responsible for plaintiffs' cancers.

The $4.7 billion talc verdict against Johnson & Johnson is set for appeals after a judge affirmed and entered the decision this week.

Trump reportedly told reporters before the dinner that he would make an announcement next week that would bring down drug prices “really substantially.”

As the public plots protests, officials plan a black-tie dinner with the president and PM Theresa May—and J&J, GSK chiefs are invited.

Johnson & Johnson CEO Alex Gorsky has remade the executive pyramid with pharma head Joaquin Duato assuming responsibility for consumer products.

A long list of biopharma materials and medical devices from China have become targets of additional U.S. tariffs.